No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism

Movement Disorders

Volumn 24, Issue 10, 2009, Pages 1519-1523

  Halliday, Glenda ^a,e   Herrero, Maria Trinidad ^b   Murphy, Karen ^a   McCann, Heather ^a   Ros Bernal, Francisco ^b   Barcia, Carlos ^b   Mori, Hideo ^c   Blesa, Francisco J ^d   Obeso, José A ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF MURCIA   (Spain)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

synuclein; Monkeys; MPTP; Parkinsonism; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; EXPERIMENTAL MONKEY; HISTOPATHOLOGY; IMMUNOREACTIVITY; LEWY BODY; NERVE CELL; NEUROPATHOLOGY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; LEWY BODIES; LONGITUDINAL STUDIES; MACACA FASCICULARIS; MPTP POISONING; TYROSINE 3-MONOOXYGENASE;

EID: 69849092676     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22481     Document Type: Article

References (24)

1. Capitanio JP, Emborg ME. Contributions of non-human primates to neuroscience research. Lancet 2008;371:1126-1135.
2. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of α-synuclein in Parkinson's disease: insights from animal models. Nature Rev Neurosci 2003;4:727-738.
3. Brundin P, Li JY, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nature Rev Neurosci 2008;9:741-745.
4. Halliday G, Hely M, Reid W, Morris J. The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 2008;115:409-415.
5. Herrero MT, Hirsch EC, Kastner A, et al. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Neuroscience 1993;56:499-511.
6. Barcia C, Sanchez Bahillo A, Fernandez-Villalba E, et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 2004; 46:402-409.
7. Borras D, Ferrer I, Pumarola M. Age-related changes in the brain of the dog. Vet Pathol 1999;36:202-211.
8. Dickson DW, Wertkin A, Kress Y, Ksiezak-Reding H, Yen SH. Ubiquitin immunoreactive structures in normal human brains. Distribution and developmental aspects. Lab Invest 1990;63:87-99.
9. Iseki E, Odawara T, Li F, et al. Age-related ubiquitin-positive granular structures in non-demented subjects and neurodegenerative disorders. J Neurol Sci 1996;142:25-29.
10. Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000;11:211-213.
11. Purisai MG, McCormack AL, Langston WJ, Johnston LC, Di Monte DA. α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 2005;20: 898-906.
12. McCormack AL, Mak SK, Shenasa M, Langston WJ, Forno LS, Di Monte DA. Pathologic modifications of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol 2008;67:793-802.
13. Eslamboli A, Romero-Ramos M, Burger C, et al. Long-term consequences of human α-synuclein overexpression in the primate ventral midbrain. Brain 2007;130:799-815.
14. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile Parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15:884-888.
15. Sasaki S, Shirata A, Yamane K, Iwata M. Parkin-positive autosomal recessive juvenile Parkinsonism with a-synuclein-positive inclusions. Neurology 2004;63:678-682.
16. Gouider-Khouja N, Larnaout A, Amouri R, et al. Autosomal recessive Parkinsonism linked to parkin gene in a Tunisian family. Clinical, genetic and pathological study. Parkinsonism Relat Disord 2003;9:247-251.
17. Mori H, Kondo T, Yokochi M, et al. Pathologic and biochemical studies of juvenile Parkinsonism linked to chromosome 6q. Neurology 1998;51:890-892.
18. Braak H, Del Tredici K. Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 2008;70:1916 1925.
19. Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. Biochem Soc Trans 2005;33:578-581.
20. Kempster PA, Williams DR, Selikhova M, Holton J, Revesz T, Lees AJ. Patterns of levodopa response in Parkinson's disease: clinico-pathological study. Brain 2007;130:2123-2128.
21. Levy G. The relationship of Parkinson disease with aging. Arch Neurol 2007;64:1242-1246.
22. Chu Y, Kordower JH. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: is this the target for Parkinson's disease? Neurobiol Dis 2007; 25:134-149.
23. Li W, Lesuisse C, Xu Y, Troncoso JC, Price DL, Lee MK. Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J Neurosci 2004;24:7400-7409.
24. Klivenyi P, Siwek D, Gardian G, et al. Mice lacking α-synuclein are resistant to mitochondrial toxins. Neurobiol Dis 2006;21: 541-548.